<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1302">
  <stage>Registered</stage>
  <submitdate>25/09/2006</submitdate>
  <approvaldate>25/09/2006</approvaldate>
  <nctid>NCT00380874</nctid>
  <trial_identification>
    <studytitle>Prevention And Treatment Of Chemotherapy-Induced Peripheral Neuropathy In Subjects With Advanced Colorectal Cancer</studytitle>
    <scientifictitle>A Randomized, Double-Blind, Placebo-Controlled Trial Of The Prevention And Treatment Of Chemotherapy-Induced Peripheral Neuropathy Symptoms In Subjects With Advanced Colorectal Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>A0081124</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chemotherapy-Induced Peripheral Neuropathy</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Pregabalin
Treatment: drugs - Placebo

Experimental: 1 - flexible dosing

Placebo Comparator: 2 - 


Treatment: drugs: Pregabalin
150- 600 mg/day (double blind in divided doses)

Treatment: drugs: Placebo
Placebo

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Duration Adjusted Average Change (DAAC) of Paresthesia From the Onset of Chemotherapy Measured by Numeric Rating Scale (NRS)</outcome>
      <timepoint>Period of 10 days from the onset of chemotherapy to the last cycle: Last Observation Carried Forward (LOCF)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Duration Adjusted Average Change (DAAC) of Paresthesic Symptom Score Within Each Cycle of Chemotherapy Measured by Numeric Rating Scale (NRS)</outcome>
      <timepoint>Baseline to Cycle 9</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration Adjusted Average Change (DAAC) of Dysesthesia Symptom Score Within Each Cycle of Chemotherapy Measured by Numeric Rating Scale (NRS)</outcome>
      <timepoint>Baseline to Cycle 9, LOCF cycle endpoint</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration Adjusted Average Change (DAAC) of Pain Symptom Score Within Each Cycle of Chemotherapy Measured by Numeric Rating Scale (NRS)</outcome>
      <timepoint>Baseline to Cycle 9, LOCF cycle endpoint</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Pain Scores Rated on Neuropathic Pain Symptom Inventory (NPSI) Subscales From Baseline Cycle</outcome>
      <timepoint>Baseline to Cycle 9, Last Observation Carried Forward (LOCF) cycle endpoint</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Persistent Paresthesic, Dysesthesic, and Pain Symptoms</outcome>
      <timepoint>Cycle 9 and Last Observation Carried Forward (LOCF) cycle endpoint</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Diagnosis of cytological confirmed carcinoma of the Colon Stage III (Dukes C) or
             metastatic Colorectal Cancer (Dukes D)

          -  Independent of this protocol, the patient has decided to receive standard of care for
             the treatment of cancer with oxaliplatin combined with 5-fluorouracil/folinic acid
             (5-FU/FA) for a minimum of 9 cycles</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Presence of neuropathic pain or peripheral polyneuropathy or identified causes of
             painful paresthesia including radiotherapy-induced or malignant plexopathy, lumbar or
             cervical radiculopathy existing prior to baseline

          -  Any patients who are not suitable to be treated with either Oxaliplatin and/or 5-FU/FA
             or pregabalin according to the respective local labeling</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>64</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA</recruitmentstate>
    <hospital>Pfizer Investigational Site - St. Leonards</hospital>
    <hospital>Pfizer Investigational Site - Adelaide</hospital>
    <postcode>2065 - St. Leonards</postcode>
    <postcode>5000 - Adelaide</postcode>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bielefeld</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Chieti Scalo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Potenza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gyeonggi-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Cantabria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Alicante</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Jaen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung Hsien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Prevention and treatment of the severity of symptoms of chemotherapy-induced peripheral
      neuropathy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00380874</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>